Persistence and compliance to antidepressant treatment in patients with depression: A chart review

Sawada, Norifusa; Uchida, Hiroyuki; Suzuki, Takefumi; Watanabe, Koichiro; Kikuchi, Toshiaki; Handa, Takashi; Kashima, Haruo

doi:10.1186/1471-244x-9-38

Cited by 160 publications

(139 citation statements)

References 33 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…In these patients, unhealthy cognition was effectively treated; therefore, prognosis was improved and the risk of recurrence was reduced. This finding was consistent with other relevant reports [26,27]. Age was the next important factor.…”

Section: Discussionsupporting

confidence: 83%

Bibliotherapy for Chinese Patients with Depression in Rehabilitation

Wang¹

2012

Mental Illnesses - Understanding, Prediction and Control

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Bibliotherapy for Chinese Patients with Depression in Rehabilitation

Wang¹

2012

Mental Illnesses - Understanding, Prediction and Control

View full text Add to dashboard Cite

“…218,219 Steady-state concentrations are reached within a few days. 215,221 The drug shows linear pharmacokinetics over the therapeutic dose range (see Table 2). 218 Age and gender influence milnacipran plasma levels but dose adjustment is not necessary.…”

Section: Milnacipranmentioning

confidence: 99%

“…Moreover, 63.1% patients who discontinued therapy did so without consulting their physicians. 221 Reasons for treatment discontinuation are multifactorial. Symptoms of depression such as poor concentration and motivation may predispose patients to noncompliance.…”

Section: Compliancementioning

confidence: 99%

See 1 more Smart Citation

Getting the balance right: Established and emerging therapies for major depressive disorders

Perović

Jovanović²,

Miljković³

et al. 2010

NDT

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.

show abstract

“…during the six months prior to inclusion • Compliance [37] to recommended SSRIs prescription defined by both a duration of antidepressant treatment consistent with a depressive episode and a time between two prescription renewals consistent with uninterrupted treatment • Treatment for a period of at least 6 month from the date of inclusion [5] …”

Section: Study Populationmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study

Peron¹,

JB²

2016

Adv Pharmacoepidemiol Drug Saf

View full text Add to dashboard Cite

Introduction: According to the French health authorities' guidelines relative to depression and anxiety disorder treatments, six Selective Serotonin Reuptake Inhibitors are available for prescription as a first-line of treatment. The guidelines suggest equivalence between these treatment options, but studies diverge regarding efficacy and safety profiles. Moreover, conditions in clinical trials are strictly controlled and do not truly reflect real life utilization. The objective of this study was to evaluate differences in efficacy and/or safety between these six selective serotonin reuptake inhibitors in real conditions of use.

show abstract

Persistence and compliance to antidepressant treatment in patients with depression: A chart review

Cited by 160 publications

References 33 publications

Bibliotherapy for Chinese Patients with Depression in Rehabilitation

Bibliotherapy for Chinese Patients with Depression in Rehabilitation

Getting the balance right: Established and emerging therapies for major depressive disorders

Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study

Contact Info

Product

Resources

About